---
layout: default
title: Apis Mellifera Arctium Lappa Root Arsenic Trioxide
parent: 僅模型預測 (L5)
nav_order: 383
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Arctium Lappa Root Arsenic Trioxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Homeopathic Multi-Ingredient Complex: Insufficient Data for Drug Repurposing Evaluation

## One-Sentence Summary

This candidate is a complex homeopathic combination containing 25 ingredients — including animal venoms, botanical extracts, heavy metals, and minerals — with no registered indication, no US market approval, and no DrugBank identifier.
The TxGNN pipeline returned **no predicted indications** for this entry, and no supporting clinical trials or publications were retrieved.
As a result, a standard repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This entry contains 25 co-listed active ingredients spanning three pharmacologically distinct categories:

**Animal-derived venoms and secretions** (9 substances): *Apis mellifera*, *Crotalus horridus horridus*, *Lachesis muta*, *Micrurus corallinus*, *Naja naja*, *Vipera berus*, *Lytta vesicatoria* (cantharidin source).

**Botanical extracts** (10 substances): *Arctium lappa*, *Cinchona officinalis*, *Colchicum autumnale*, *Convallaria majalis*, *Echinacea*, *Juniper berry*, *Sambucus nigra*, *Solidago virgaurea*, *Taraxacum officinale*, *Thuja occidentalis*, *Toxicodendron pubescens*, *Urtica urens*, *Strophanthus hispidus*.

**Inorganic compounds** (3 substances): Arsenic trioxide, mercury, sodium carbonate, sodium sulfate.

The TxGNN knowledge graph is designed to model single-entity or well-characterised combination drugs with defined DrugBank identifiers. This entry lacks a DrugBank ID, has no mapped INN, and its multi-ingredient profile cannot be meaningfully collapsed into a single pharmacological node. Consequently, the model produced zero prediction candidates.

It should be noted that several individual components have established pharmacological relevance (e.g., arsenic trioxide as an antineoplastic agent in APL; colchicine from *Colchicum autumnale* in gout; digitalis glycosides in heart failure), but these activities belong to the individual purified constituents — not to this combined preparation as presented.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination.

---

## Literature Evidence

Currently no related literature available for this specific multi-ingredient combination as a unified drug entity.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers:** Several individual ingredients in this combination carry significant inherent toxicity. Arsenic trioxide is a known carcinogen and requires strict haematological monitoring when used therapeutically. Mercury-containing compounds carry nephrotoxic and neurotoxic risk. Colchicum alkaloids are cardiotoxic and cytotoxic at non-homeopathic doses. Animal venoms contain enzymatic and neurotoxic fractions. Although homeopathic preparations are typically prepared at ultra-high dilutions where pharmacological activity is debated, the absence of a package insert and formal safety profile for this combination makes it impossible to characterise its actual risk.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This entry could not be evaluated because TxGNN generated no repurposing predictions, no regulatory approval exists in any tracked jurisdiction, no DrugBank identifier is available, and all safety data are absent. The multi-ingredient homeopathic format is structurally incompatible with single-drug repurposing frameworks without decomposition into individual components.

**To proceed, the following is needed:**

- **Decompose the combination**: Evaluate each pharmacologically active ingredient (arsenic trioxide, colchicine alkaloids, digitalis glycosides, *Cinchona* alkaloids) independently through separate TxGNN pipelines using their respective DrugBank IDs.
- **Establish regulatory identity**: Determine whether this is a registered homeopathic product in any jurisdiction and obtain the formal product label.
- **Clarify clinical context**: Identify the therapeutic area this combination is intended for (e.g., oncology supportive care, cardiovascular, immunomodulation) before scoping a repurposing hypothesis.
- **Safety documentation**: Obtain or reconstruct a minimum safety profile, including dilution levels for toxic components (arsenic, mercury, venoms), before any clinical development discussion.
- **DrugBank mapping**: Assign individual DrugBank IDs to each active ingredient to enable knowledge graph traversal.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

